The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Oral Oncology

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.oraloncology.2016.08.001PMID 27503244PMCID PMC5690560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

  2018cited by this paper
• PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

  2017cited by this paper
• Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

  2016cited by this paper
• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.

  2016cited by this paper
• Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

  2016cited by this paper
• Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma

  2015cited by this paper
• Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

  2015cited by this paper
• Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.

  2015cited by this paper
• Antagonists of PD-1 and PD-L1 in Cancer Treatment.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.

  2014cited by this paper
• Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.

  2014cited by this paper
• RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2013cited by this paper
• Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer

  2013cited by this paper
• CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma.

  2013cited by this paper
• Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.

  2013cited by this paper
• Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  2013cited by this paper
• PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

  2012cited by this paper
• The expression, function, and clinical relevance of B7 family members in cancer

  2012cited by this paper
• Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

  2012cited by this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine

  2012cited by this paper
• Dual biological effects of the cytokines interleukin-10 and interferon-γ

  2011cited by this paper
• The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

  2011cited by this paper
• Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.

  2011cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors

  2010cited by this paper
• B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

  2010cited by this paper
• The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

  2009cited by this paper
• Interaction of human PD-L1 and B7-1.

  2008cited by this paper
• Epitope landscape in breast and colorectal cancer.

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

  2007cited by this paper
• PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors.

  2007cited by this paper
• Expression of B7‐H1 in breast cancer patients is strongly associated with high proliferative Ki‐67‐expressing tumor cells

  2007cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.

  2006cited by this paper
• Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

  2006cited by this paper
• Corrigendum: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

  2006cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer

  2006cited by this paper
• PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

  2006cited by this paper
• PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

  2006cited by this paper
• Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

  2005cited by this paper
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

  2004cited by this paper
• Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses.

  2004cited by this paper
• Costimulation-based immunotherapy for head and neck cancer

  2004cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations.

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

  2001cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen.

  1994cited by this paper
• B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells

  1994cited by this paper
• B70 antigen is a second ligand for CTLA-4 and CD28

  1993cited by this paper
• Identification of an alternative CTLA-4 ligand costimulatory for T cell activation.

  1993cited by this paper
• Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

  1993cited by this paper
• Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.

  1993cited by this paper
• Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

  1991cited by this paper
• CTLA-4 is a second receptor for the B cell activation antigen B7

  1991cited by this paper
• T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.

  1990cited by this paper
• B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells.

  1989cited by this paper

• Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis.

  2026cites this paper
• Can the co-localization of CD8+, PD-1, PD-L1 AND PD-L2 patterns provide guidance in clinical evolution of patients with head and neck cutaneous squamous cell carcinoma?

  2025cites this paper
• Differential expression of PD-L1, PD-L2 and inflammasome related proteins (NLRP3, ASC, and Caspase-1) in oral squamous cell carcinoma, lymph node metastases, and benign lesions.

  2025cites this paper
• Effects of immune checkpoint inhibitors on the quality of life of patients with metastatic or recurrent head and neck cancer: a systematic review protocol.

  2025cites this paper
• Application and Perspectives of Immunotherapy in Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Ferroptosis and oral squamous cell carcinoma: connecting the dots to move forward

  2024cites this paper
• Increased tumor-infiltrating plasmacytoid dendritic cells express high levels of PD-L2 and affect CD8+ T lymphocyte infiltration in human laryngeal squamous cell carcinoma

  2024cites this paper
• Immuno-oncologic signature of malignant transformation in oral squamous cell carcinoma.

  2023cites this paper
• MYO5A overexpression promotes invasion and correlates with low lymphocyte infiltration in head and neck squamous carcinoma

  2023cites this paper
• Modulation of PD-L1 expression by standard therapy in head and neck cancer cell lines and exosomes

  2023cites this paper
• Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases

  2023cites this paper
• Potential multi-modal effects of provirus integration on HIV-1 persistence: lessons from other viruses.

  2022cites this paper
• In vitro models for head and neck cancer: Current status and future perspective

  2022cites this paper
• Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review)

  2022cites this paper
• Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma

  2022cites this paper
• Comprehensive analysis of macrophage-related multigene signature in the tumor microenvironment of head and neck squamous cancer

  2021cites this paper
• Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2021cites this paper
• The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis

  2021cites this paper
• cross‐analyzed for the relationship of TMC8 with immune cell infiltration and its impact on the prognosis of numerous types

  2021cites this paper
• Comprehensive co-expression analysis reveals TMC8 as a prognostic immune-associated gene in head and neck squamous cancer

  2021cites this paper
• Pharmacological and Genetic Inhibition of PD-1 Demonstrate an Important Role of PD-1 in Ischemia-Induced Skeletal Muscle Inflammation, Oxidative Stress, and Angiogenesis

  2021cites this paper
• The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.

  2020cites this paper
• Molecular and Signaling Pathways During Oral Carcinogenesis

  2020cites this paper
• Immunosuppressive Property of MSCs Mediated by Cell Surface Receptors

  2020cites this paper
• PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications

  2020cites this paper
• PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood.

  2020cites this paper
• TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2

  2019cites this paper
• Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.

  2019cites this paper
• The evolving role of immuno‐oncology for the treatment of head and neck cancer

  2019cites this paper
• The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.

  2019cites this paper
• The Head and Neck Squamous Cell Carcinoma Microenvironment as a Potential Target for Cancer Therapy

  2019cites this paper
• Advances in Immunotherapy and Periocular Malignancy

  2019cites this paper
• Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.

  2019cites this paper
• Checkpoint inhibitors in head and neck cancer

  2019cites this paper
• Head and Neck Tumors

  2019cites this paper
• University of Birmingham TLR9 mediated tumour-stroma interactions in human papilloma virus (HPV)-positive head and neck squamous cell carcinoma up-regulate PD-L1 and PD-L2

  2019cites this paper
• Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review

  2018cites this paper
• Immune checkpoint blockade therapy in head and neck cancer: a review

  2018cites this paper
• Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms

  2018cites this paper
• Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

  2018cites this paper
• Restoration of Facial Form and Lip Competence in a Patient with a Midfacial Defect

  2018cites this paper
• Postoperative anti-PD-1 antibody treatment to reduce recurrence in a cancer ablation surgical wound.

  2018cites this paper
• Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.

  2018cites this paper
• Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4

  2018cites this paper
• Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.

  2018cites this paper
• Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype

  2018cites this paper
• Induction and Analysis of Cytotoxic T-Lymphocytes that Recognize Autologous Oral Squamous Cell Carcinoma.

  2017cites this paper
• [Current events in immunotherapy for upper aerodigestive tract cancer].

  2017cites this paper
• Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma.

  2017cites this paper
• Head and neck cancer: improving outcomes with a multidisciplinary approach

  2017influential citation
• Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.

  2017cites this paper
• Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

  2017cites this paper
• Étude descriptive rétrospective et mono-centrique de la survie des patients suivis pour un cancer bronchique non à petites cellules traités par nivolumab, en fonction du statut PD-L1

  2017cites this paper
• Unknown primary head and neck squamous cell carcinoma in the era of fluorodeoxyglucose‐positron emission tomography/CT and intensity‐modulated radiotherapy

  2017cites this paper
• Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives

  2017influential citation
• Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.

  2017cites this paper
• Programmed cell death ligand 1 as a biomarker in head and neck cancer

  2017cites this paper
• HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers

  2017influential citation
• PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma

  2017influential citation
• Overexpression of immunomodulatory mediators in oral precancerous lesions.

  2017cites this paper
• Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.

  2016cites this paper